GSK PLC Sponsored ADR (NYSE:GSK) Shares Sold by Mondrian Investment Partners LTD

Key Points

• Mondrian Investment Partners LTD decreased its position in GSK PLC by 0.3%, selling 17,111 shares, and now holds approximately 5.82 million shares valued at $225.5 million.
• GSK's stock was upgraded from a "hold" to a "buy" rating by Wall Street Zen, while the company has an average rating of "Hold" with a price target of $37.38.
• GSK recently declared a quarterly dividend of $0.4206, representing an annualized dividend of $1.68, with a yield of 4.4%, and a payout ratio of 77.78%.

Mondrian Investment Partners LTD lessened its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 0.3% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,821,273 shares of the pharmaceutical company's stock after selling 17,111 shares during the period. GSK comprises approximately 3.8% of Mondrian Investment Partners LTD's investment portfolio, making the stock its 5th largest holding. Mondrian Investment Partners LTD owned 0.28% of GSK worth $225,516,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Russell Investments Group Ltd. grew its position in shares of GSK by 21.9% in the first quarter. Russell Investments Group Ltd. now owns 1,251,700 shares of the pharmaceutical company's stock valued at $48,491,000 after purchasing an additional 224,860 shares during the last quarter. Callan Family Office LLC boosted its stake in shares of GSK by 15.7% in the first quarter. Callan Family Office LLC now owns 66,791 shares of the pharmaceutical company's stock valued at $2,587,000 after buying an additional 9,079 shares during the period. HighTower Advisors LLC boosted its stake in shares of GSK by 1.3% in the first quarter. HighTower Advisors LLC now owns 287,047 shares of the pharmaceutical company's stock valued at $11,120,000 after buying an additional 3,585 shares during the period. Tranquilli Financial Advisor LLC bought a new stake in shares of GSK in the first quarter valued at approximately $221,000. Finally, Nuveen LLC bought a new stake in GSK during the first quarter worth $1,456,000. Institutional investors own 15.74% of the company's stock.

Analysts Set New Price Targets

GSK has been the subject of several recent analyst reports. Wall Street Zen upgraded GSK from a "hold" rating to a "buy" rating in a research note on Sunday, August 3rd. Berenberg Bank restated a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Finally, Hsbc Global Res upgraded GSK to a "strong sell" rating in a research note on Monday, April 28th. One analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $37.38.

GSK Price Performance

Shares of GSK traded up $0.07 during trading hours on Friday, reaching $39.30. The stock had a trading volume of 3,038,539 shares, compared to its average volume of 4,741,255. GSK PLC Sponsored ADR has a 12 month low of $31.72 and a 12 month high of $44.67. The stock has a market capitalization of $80.14 billion, a PE ratio of 18.19, a PEG ratio of 1.71 and a beta of 0.51. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. The company's 50-day moving average is $38.50 and its two-hundred day moving average is $37.95.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. The business had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%. GSK's quarterly revenue was up 1.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.43 earnings per share. Research analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be issued a $0.4206 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date is Friday, August 15th. GSK's dividend payout ratio is presently 77.78%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.